Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
business development
Biotech
Lilly’s $2.3B Ajax drug works ‘right out of the gate’
The early data showed the novel JAK2 inhibitor “started working right out of the gate, with a good safety profile,” Lilly’s Jake Van Naarden said.
Angus Liu
Jun 13, 2026 11:15am
Fierce Pharma
Inside Astellas CEO's plan to counter Xtandi's patent cliff
Jun 11, 2026 6:00pm
Fierce Pharma
Novavax bets on ‘amplification strategy’ with Sanofi, Pfizer deals
Apr 6, 2026 8:37am
With 200 JPM meetings, Novo BD head seeks out the next Metsera
Jan 27, 2026 5:25pm
Fierce Pharma
Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears
Jan 15, 2026 10:42am
Fierce Pharma
Bristol Myers CEO pledges to 'cast a broad net' in dealmaking
Jan 12, 2026 4:28pm
